Late Phase Trials
| AstraZeneca (Serena 6) | |
| Description | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression |
| Target Population | ER- Positive HER2-Negative Breast Cancer |
| Type of medication | Oral Medication |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT04964934 |
| Tempus Labs (ctDNA) | |
| Description | Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays |
| Target Population | Colorectal Cancer |
| Type of medication | Observation |
| Phase of study | N/A |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT05234177 |
| Guardant Health(Lab Study) | |
| Description | Observation of Residual Cancer With Liquid Biopsy Evaluation
(ORACLE)
|
| Target Population | Invasive bladder, ureteral, or renal pelvis carcinoma, NSCLC, breast cancer, Melanoma, Esophoageal Carcinoma, GEJ, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of Head and Neck, Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma |
| Type of medication | Observation |
| Phase of study | N/A |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT05059444 |
| Daiichi Sankyo ( TROPION –Lung08) | |
| Description | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) |
| Target Population | Metastatic Non-Small Cell Lung Cancer |
| Type of medication | Intravenous Infusion |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://www.clinicaltrials.gov/ct2/show/NCT05215340 |
| Epizyme, Inc. (Symphony-1) | |
| Description | Study in Subjects With Relapsed/Refractory Follicular Lymphoma |
| Target Population | Relapsed/Refractory Follicular Lymphoma |
| Type of medication | Intravenous Infusion and Oral Medication |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT04224493 |
| Bristol-Myers Squibb (SUCCESSOR-1) | |
| Description | A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (Successor-1) |
| Target Population | Relapsed or Refractory Multiple Myeloma |
| Type of medication | Intravenous Infusion and Oral Medication |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT05519085 |
| Merus N.V. (MCLA-128) (eNRGy) | |
| Description | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion |
| Target Population | Solid Tumors Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion Pancreatic Cancer Harboring NRG1 Fusion NRG1 Fusion |
| Type of medication | Intravenous Infusion |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT02912949 |
| Daiichi Sankyo (TROPION-Lung07) | |
| Description | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
| Target Population | Metastatic Non Small Cell Lung Cancer |
| Type of medication | IV |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT05555732 |
| GenMab 1042 | |
| Description | GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors |
| Target Population | Head and Neck Squamous Cell Carcinoma |
| Type of medication | IV |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT04083599 |
| Merck 7902-009 (LEAP-009) | |
| Description | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy |
| Target Population | Head and Neck Squamous Cell Carcinoma |
| Type of medication | Intravenous Infusion and Oral Medication |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT04428151 |
| PharmaMar LAGOON | |
| Description | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) |
| Target Population | Small Cell Lung Cancer |
| Type of medication | Intravenous Infusion |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://classic.clinicaltrials.gov/ct2/show/NCT05153239 |
| Novartis CABL001AUSO8 | |
| Description | Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) |
| Target Population | Chronic Phase CML |
| Type of medication | Oral Medication |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/study/NCT05384587 |
| Aadi Bioscience | |
| Description | Phase 2 Basket Trial of Nab-sirolimus in Patients with Malignant Solid Tumors with Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) |
| Target Population | Solid Tumor |
| Type of medication | Intravenous Infusion |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/study/NCT05103358 |
| Henlius | |
| Description | To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
| Target Population | Small Cell Lung Cancer |
| Type of medication | Intravenous Infusion |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://classic.clinicaltrials.gov/ct2/history/NCT05468489 |
| Merck Keynote-975 | |
| Description | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) |
| Target Population | Esophageal Carcinoma |
| Type of medication | Intravenous Infusion |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/study/NCT04210115 |
| BTO | |
| Description | Billion To One Northstar Response Clinical Validation Study |
| Target Population | Advanced or Metastatic Cancer Starting a New Line of Therapy |
| Type of medication | N/A |
| Phase of study | N/A |
| Available at | Utah Cancer Specialists |
| Janssen (Majes TEC-9) | |
| Description | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) |
| Target Population | Relapsed or Refractory Multiple Myeloma |
| Type of medication | Intravenous Infusion and Oral Medication |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://www.clinicaltrials.gov/study/NCT05572515 |
| Artios (Tempus) | |
| Description | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors |
| Target Population | Advanced Cancer
Primary Peritoneal Cancer Ovarian Cancer Metastatic Cancer Fallopian Tube Cancer |
| Type of medication | Intravenous Infusion and Oral Medication |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/study/NCT04657068 |
| AstraZeneca Cambria-1 | |
| Description | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) |
| Target Population | Breast |
| Type of medication | Oral Medication |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://classic.clinicaltrials.gov/ct2/show/NCT05774951 |
| Cardiff 04 | |
| Description | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation |
| Target Population | Metastatic Colorectal Cancer
CRC KRAS/NRAS Mutation |
| Type of medication | Intravenous Infusion and Oral Medication |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://classic.clinicaltrials.gov/ct2/show/NCT06106308 |
| CG Pharmaceuticals | |
| Description | A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
|
| Target Population | Pancreatic Adenocarcinoma |
| Type of medication | Intravenous Infusion & Oral |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | |
| Boehringer Ingelheim (BI 907828) | |
| Description | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma |
| Target Population | Dedifferentiated Liposarcoma |
| Type of medication | Oral Medication |
| Phase of study | III |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/ct2/show/NCT06058793 |
| Zentalis | |
| Description | A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Target Population | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Type of medication | Oral |
| Phase of study | II |
| Available at | Utah Cancer Specialists |
| Link | https://clinicaltrials.gov/study/NCT05128825 |